1073 related articles for article (PubMed ID: 19584384)
1. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
3. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry.
Levine DP; Lamp KC
Am J Med; 2007 Oct; 120(10 Suppl 1):S28-33. PubMed ID: 17904948
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of daptomycin in complicated skin and skin-structure infections due to methicillin-sensitive and -resistant Staphylococcus aureus: results from the CORE Registry.
Martone WJ; Lamp KC
Curr Med Res Opin; 2006 Dec; 22(12):2337-43. PubMed ID: 17257448
[TBL] [Abstract][Full Text] [Related]
5. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
Mohr JF; Friedrich LV; Yankelev S; Lamp KC
Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
[TBL] [Abstract][Full Text] [Related]
6. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
[TBL] [Abstract][Full Text] [Related]
7. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Ardura MI; Mejías A; Katz KS; Revell P; McCracken GH; Sánchez PJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
[TBL] [Abstract][Full Text] [Related]
8. Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic.
Cosgrove SE; Vigliani GA; Fowler VG; Abrutyn E; Corey GR; Levine DP; Rupp ME; Chambers HF; Karchmer AW; Boucher HW
Clin Infect Dis; 2009 Mar; 48(6):713-21. PubMed ID: 19207079
[TBL] [Abstract][Full Text] [Related]
9. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
[TBL] [Abstract][Full Text] [Related]
10. Daptomycin in the treatment of bacteremia.
Sakoulas G; Golan Y; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S21-7. PubMed ID: 17904947
[TBL] [Abstract][Full Text] [Related]
11. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients.
Segreti JA; Crank CW; Finney MS
Pharmacotherapy; 2006 Mar; 26(3):347-52. PubMed ID: 16503714
[TBL] [Abstract][Full Text] [Related]
12. Safety of daptomycin in patients receiving hemodialysis.
Mueller BA; Crompton JA; Donovan BJ; Yankalev S; Lamp KC
Pharmacotherapy; 2011 Jul; 31(7):665-72. PubMed ID: 21923453
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
Katz DE; Lindfield KC; Steenbergen JN; Benziger DP; Blackerby KJ; Knapp AG; Martone WJ
Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172
[TBL] [Abstract][Full Text] [Related]
14. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
Owens RC; Lamp KC; Friedrich LV; Russo R
Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
[TBL] [Abstract][Full Text] [Related]
15. Daptomycin experience in critical care patients: results from a registry.
Brown JE; Fominaya C; Christensen KJ; McConnell SA; Lamp KC
Ann Pharmacother; 2012 Apr; 46(4):495-502. PubMed ID: 22454446
[TBL] [Abstract][Full Text] [Related]
16. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with daptomycin: bacteraemia and endocarditis.
Levine DP
J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistant gram-positive infections in patients with ventricular assist devices: the role of daptomycin.
Beiras-Fernandez A; Kur F; Kiefer S; Sodian R; Schmoeckel M; Weis M; Reichart B; Weis F
Transplant Proc; 2009; 41(6):2589-91. PubMed ID: 19715980
[TBL] [Abstract][Full Text] [Related]
19. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry.
Rolston KV; McConnell SA; Brown J; Lamp KC
Clin Adv Hematol Oncol; 2010 Apr; 8(4):249-56, 90. PubMed ID: 20505648
[TBL] [Abstract][Full Text] [Related]
20. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis.
Forrest GN; Donovan BJ; Lamp KC; Friedrich LV
Ann Pharmacother; 2008 Feb; 42(2):213-7. PubMed ID: 18212253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
